Tailoring irAE Care to Specific Patients

This activity is part of a series


Veronica B. Ajewole, PharmD, BCOP
Associate Professor of Pharmacy Practice
Texas Southern University
Clinical Pharmacist Specialist, Oncology
Houston Methodist Hospital, Houston, TX
Veronica B. Ajewole, PharmD, BCOP

Dr. Ajewole serves as Associate Professor in the Department of Pharmacy Practice at Texas Southern University (TSU) and as a Clinical Pharmacist and an Adjunct Assistant Professor of Oncology at Houston Methodist Hospital. She received her PharmD from TSU and completed her oncology pharmacy residency at Houston Methodist Hospital. Dr. Ajewole is a board-certified Oncology Pharmacist with clinical practice in oral chemotherapy at Houston Methodist Hospital Cancer Center.

Dr. Ajewole and her team received a Susan G. Komen community grant to establish a Breast Cancer Screening and Prevention Center at TSU. She is the Director of the recently funded National Institutes of Health-Research Centers in Minority Institutions Center for Biomedical and Minority Health Research – Community Engagement Core. Dr. Ajewole is also the Principal Investigator of a Centers for Medicare & Medicaid Services-funded grant on prostate cancer in African American men and a Cancer Prevention and Research Institute of Texas-funded grant on breast cancer prevention program for ethnic minority women. She is the founder of Community Resource Solutions Group: an organization committed to promoting Health Equity, Research, and Training. Learn more at www.communityrsg.com

When Dr. Ajewole is not serving her patients, students, community, or church, she is serving and enjoying quality time with her husband and four wonderful children.

Ana I. Velázquez Mañana, MD, MSc
Assistant Professor, Division of Hematology Oncology, Zuckerberg San Francisco General Hospital
Assistant Director of Diversity, Equity, Inclusion and Accessibility, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Ana I. Velázquez Mañana, MD, MSc

Dr. Ana Velázquez Mañana is a thoracic oncologist and Assistant Professor of Medicine in the University of California, San Francisco (UCSF) Division of Hematology/Oncology at Zuckerberg San Francisco General Hospital in California. As a Latina, she advocates for workforce diversity and gender equity and has been named the Assistant Director of Diversity, Equity, Inclusion, and Accessibility for Training of the Helen Diller Family Comprehensive Cancer Center at UCSF. Dr. Velázquez completed her MD at the University of Puerto Rico School of Medicine, a Master of Biomedical Science at Mayo Clinic Graduate School of Biomedical Sciences (formerly known as Mayo Graduate School), and her Internal Medicine residency at Mount Sinai Beth Israel, where she was a Chief Resident. She joined UCSF in 2018, where she completed her clinical fellowship in Medical Oncology and postdoctoral research fellowship in the National Clinician Scholars Program.

Dr. Velázquez is a member of the prestigious John A. Watson Faculty Scholars Class of 2022 at UCSF and has been awarded a Conquer Cancer Foundation Young Investigator Award. She aims to support and improve the outcomes of patients with lung cancer from vulnerable backgrounds using health services and disparities research.

Statement of Need

Increasing use of immune checkpoint inhibitors (ICIs) for the treatment of cancer has led to an increasing incidence of immune related adverse events (irAEs). Cutaneous toxicities are some of the most common irAE manifestations, but clinicians may be less trained to recognize signs and symptoms in non-White patients. Social determinants of health that may impact a patient’s ability to receive recommended treatment for irAEs include geographic location, transportation difficulties, low income, and language barriers. Implicit and explicit biases may impact a patient’s ability to receive guideline-recommended care from healthcare team members. Focused efforts are needed to address health care inequities in patients being treated with ICIs and to improve chances of achieving the best possible outcomes for all patients. Clinicians need to incorporate considerations for health care disparities into care planning to effectively manage irAEs in historically disadvantaged patient populations.

In this CMEO BriefCase, expert faculty will present information on how healthcare disparities impact irAE recognition and management and pharmacist considerations for social determinants of health relative to irAE diagnosis and treatment planning. Discussion will include strategies for addressing healthcare inequities in order to improve timely recognition and treatment for all patients experiencing irAEs.

Learning Objective

Upon completion of this activity, learners will be better able to develop tactics for addressing health care disparities in patients experiencing irAEs.

Financial Support

Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Target Audience

Pharmacists in outpatient, ambulatory, or community care settings.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-025-H01-P

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Ajewole reports no financial relationships to disclose.

Dr. Velázquez Mañana reports the following financial relationships:

Advisory Board: AstraZeneca

Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc.

Other Financial or Material Support: Honoraria: Curio Science and MJH Life Sciences; Travel/accommodations: Bio Ascend and DAVA

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:

  • Elizabeth Naber, MSN, RN, CCRN-K, CNRN, TCRN (peer reviewer)
  • Thomas Mitchell (planning committee)
  • Kasey Brandt, PharmD (planning committee)
  • Julie Strickland, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Tailoring irAE Care to Specific Patients
Event Date: 04/27/2023